Tag: Cml treatment

In 2001, the U.S. Food and Drug Administration (FDA) approved imatinib (brand name Gleevec), marking a monumental shift in cancer treatment as it was the first rationally designed kinase inhibitor to directly target a specific cancer-causing protein. Its approval opened the door to a new era of precision medicine, demonstrating that targeted therapy could be a safe and highly effective alternative to conventional chemotherapy.

According to the U.S. Food and Drug Administration (FDA), the generic name for Synribo is omacetaxine mepesuccinate. This medication was developed to treat certain forms of chronic myeloid leukemia (CML) in patients who had become resistant to or intolerant of other therapies. It is important to note that Synribo has been permanently discontinued and is no longer available in the U.S. market.